ADMA Biologics (ADMA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

ADMA Biologics

NasdaqGM•Healthcare•Biotechnology

$9.11+0.16(0.02%)After hours

Market Cap

$2.08B

P/E

12.3x

P/S

4.1x

P/B

5.1x

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

How this company scores

GoodMetricSide Score: 69/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Growth (13/25).

Profitability16/25

Growth13/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality19/25

Strengths

Rising free cash flowStrong marginsHigh ROELow leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 12.3x5y range 12.3x – 74.7x

Currently below its 9-quarter median.

P/S · 4.1x5y range 2.2x – 12.2x

Currently near its 20-quarter median.

P/B · 5.1x5y range 1.3x – 20.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.4x) — earnings may be inflated by non-cash items or aggressive accounting.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $2.08B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $512.27M
Q. Revenue: $124.39M
TTM EBITDA: $231.98M
TTM Op. Income: $224.48M
Q. Op. Income: $52.45M
TTM Net Income: $168.96M
Q. Net Income: $37.82M
EPS: $0.17
Shares Out.: $228.23M

$512.27M in TTM revenue grew 8.0% YoY, reaching $124.39M last quarter. TTM EBITDA of $231.98M and TTM operating income of $224.48M show growth is flowing through to the bottom line. TTM net income of $168.96M means revenue is converting into profit. Over the past year, TTM revenue is up 8% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 69.4%
EBITDA Margin: 43.5%
Op. Margin: 42.2%
Net Margin: 30.4%

Op. margin of 42.2% is up 7.1% YoY — cost efficiency is improving. Net margin at 30.4% and gross margin of 69.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 20% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 12.3x
P/S Ratio: 4.1x
P/B Ratio: 5.1x

At 12.3x P/E, the stock trades below typical market levels. P/S of 4.1x and P/B of 5.1x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $684.21M
Cash: $136.02M
Long-Term Debt: $192.84M
Book Value: $408.21M
D/E Ratio: 0.5
Debt/EBITDA: 3.6

With $684.21M in assets and $192.84M in long-term debt, D/E is 0.5and book value is $408.21M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 0% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $29.54M
TTM Free Cash Flow: $116.47M
FCF Margin: 22.7%
FCF / Net Income: 0.7

TTM FCF of $116.47M on $29.54M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.